Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6717933 | 0.89 | LTA4H (0.58) | LTA4HLMNAPOLBMAPTHTT | |
| SCHEMBL13726322 | 0.86 | LMNA (0.57) | LTA4HLMNAPOLBMAPTHTT | |
| SCHEMBL3823095 | 0.86 | LTA4H (0.62) | LTA4HLMNAPOLBMAPTHTT | |
| SCHEMBL5314854 | 0.82 | ALOX5 (0.53) | LTA4H | |
| SCHEMBL8302564 | 0.79 | MEN1 (0.51) | LTA4HLMNAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL2987817 | 0.77 | RAB9A (0.74) | LTA4HRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL24207746 | 0.76 | L3MBTL1 (0.46) | LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL25047613 | 0.76 | LTA4H (0.53) | LTA4H | |
| SCHEMBL7857951 | 0.76 | PSMB5 (0.46) | LMNAPOLBMAPTHTTRAB9A | |
| SCHEMBL7043590 | 0.76 | LTA4H (0.62) | LTA4HRAB9ASMN1; SMN2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011759-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| EP-2152669-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | Cephalon, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| EP-1904484-B1 | COMPOUNDS | GLAXO GROUP LTD (GB) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008137087-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080207638-A1 | Compounds | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080207638-A1 | Compounds | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (GB) | 2008-08-28 | — | — | US | disclosed |
| WO-2007009739-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009741-A1 | PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207638-A1 | Compounds | CMA1, MRGPRX2, HRH2 | LTA4H 21/4885LMNA 2529/4885POLB 3167/4885 |
| US-20150011759-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | TPMT, SPR, QDPR | LTA4H 4357/4885LMNA 4225/4885POLB 799/4885 |
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | HRH3, HRH1, HRH4 | LTA4H 204/4885LMNA 3821/4885POLB 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.